ECSP109885A - Compuestos de cinolina para su uso en el tratamiento de la esquizofrenia - Google Patents

Compuestos de cinolina para su uso en el tratamiento de la esquizofrenia

Info

Publication number
ECSP109885A
ECSP109885A EC2010009885A ECSP109885A ECSP109885A EC SP109885 A ECSP109885 A EC SP109885A EC 2010009885 A EC2010009885 A EC 2010009885A EC SP109885 A ECSP109885 A EC SP109885A EC SP109885 A ECSP109885 A EC SP109885A
Authority
EC
Ecuador
Prior art keywords
compounds
treatment
chichophrenia
cinoline
schizophrenia
Prior art date
Application number
EC2010009885A
Other languages
English (en)
Inventor
Marc Chapdelaine
Jeffrey Louis Arriza
Edward Christian
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39811856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP109885(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP109885A publication Critical patent/ECSP109885A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención se relaciona con el uso de los compuestos que tienen la fórmula I estructural que se muestra a continuación: y sus sales farmacéuticamente aceptables, tautómeros o precursores hidrolizables in vivo,composiciones en el tratamiento de la esquizofrenia.
EC2010009885A 2007-06-19 2010-01-19 Compuestos de cinolina para su uso en el tratamiento de la esquizofrenia ECSP109885A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94488307P 2007-06-19 2007-06-19

Publications (1)

Publication Number Publication Date
ECSP109885A true ECSP109885A (es) 2010-02-26

Family

ID=39811856

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010009885A ECSP109885A (es) 2007-06-19 2010-01-19 Compuestos de cinolina para su uso en el tratamiento de la esquizofrenia

Country Status (15)

Country Link
US (2) US20080318925A1 (es)
EP (1) EP2167091A1 (es)
JP (1) JP2010530406A (es)
KR (1) KR20100039340A (es)
AR (1) AR067028A1 (es)
AU (1) AU2008264985A1 (es)
BR (1) BRPI0813253A2 (es)
CA (1) CA2691648A1 (es)
CL (1) CL2008001837A1 (es)
EC (1) ECSP109885A (es)
IL (1) IL202496A0 (es)
PE (1) PE20090771A1 (es)
TW (1) TW200911760A (es)
UY (1) UY31161A1 (es)
WO (1) WO2008155573A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5148507B2 (ja) * 2005-12-20 2013-02-20 アストラゼネカ・アクチエボラーグ Ｇａｂａａ受容体調節物質としての置換シンノリン誘導体及びその合成法
US7465795B2 (en) * 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
WO2010123441A1 (en) * 2009-04-21 2010-10-28 Astrazeneca Ab Crystalline form of 4-amino-8-(2-fluoro-6-methoxy-phenyl)-n-propylcinnoline-3- carboxamide hydrogen sulphate, for treatment of anxiety disorders
WO2011021979A1 (en) * 2009-08-18 2011-02-24 Astrazeneca Ab Cinnoline compounds, their preparation, and their use
CN105541759A (zh) * 2016-01-07 2016-05-04 美吉斯制药（厦门）有限公司 一种制备沃替西汀的新方法
US12415830B2 (en) * 2019-01-08 2025-09-16 Chengdu kanghong pharmaceutical co ltd Steroid compound, and use thereof and preparation method therefor
AU2024259614A1 (en) * 2023-04-18 2025-10-02 Vanderbilt University Thiazolopyridine derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor m4

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230713A (en) * 1979-01-19 1980-10-28 Ici Americas Inc. Heterocyclic tetrahydro-1-alkyl-4-oxo-1H-imidazol-2-ylidene urea and phenyl esters of tetrahydro-1-alkyl-4-oxo-1H-imidazol-2-ylidene carbamic acid compounds
GB8310266D0 (en) * 1982-05-12 1983-05-18 Ici America Inc Pyrazolopyridine compounds
US4552883A (en) * 1982-06-15 1985-11-12 Ici Americas Inc. Pyrazolo[3,4-b]pyridine carboxylic acid esters and their pharmaceutical use
US4563525A (en) * 1983-05-31 1986-01-07 Ici Americas Inc. Process for preparing pyrazolopyridine compounds
GB8329531D0 (en) * 1983-11-04 1983-12-07 Ici America Inc Pyrazolopyridine cycloalkanones
GB8421116D0 (en) * 1984-08-20 1984-09-26 Ici America Inc Alkynyl derivatives
GB8425104D0 (en) * 1984-10-04 1984-11-07 Ici America Inc Amide derivatives
GB8513639D0 (en) * 1985-05-30 1985-07-03 Ici America Inc Cinnoline compounds
GB8610980D0 (en) * 1986-05-06 1986-06-11 Ici America Inc Heterocyclic fused tricyclic compounds
DD249011A5 (de) * 1986-06-20 1987-08-26 Ici Americas Inc,Us Verfahren zur herstellung von cinnolin-verbindungen
GB8702288D0 (en) * 1987-02-02 1987-03-11 Erba Farmitalia Cinnoline-carboxamides
ATE79540T1 (de) * 1988-02-09 1992-09-15 Ici America Inc Pharmazeutische zusammensetzung.
US4925844A (en) * 1988-02-09 1990-05-15 Ici Americas Inc. Antagonizing the pharmacological effects of a benzodiazepine receptor agonist
US5190951A (en) * 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US5240934A (en) * 1990-10-19 1993-08-31 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5750088A (en) * 1993-03-30 1998-05-12 The Dupont Merck Pharmaceutical Company Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals
ES2150688T3 (es) * 1995-07-25 2000-12-01 Clariant Gmbh Procedimiento para la realizacion de reacciones de acoplamiento cruzado.
DE19620023C2 (de) * 1996-05-17 2001-03-08 Celanese Chem Europe Gmbh Verfahren zur Herstellung von Phosphinat- oder Phosphonatgruppen enthaltenden tertiären Phosphanen und neue Phosphinatgruppen enthaltende tertiäre Phosphane
CA2321791A1 (en) * 1998-03-18 1999-09-23 Ciba Specialty Chemicals Holding Inc. Coupling reactions with palladium catalysts
US6362216B1 (en) * 1998-10-27 2002-03-26 Array Biopharma Inc. Compounds which inhibit tryptase activity
DE19916222A1 (de) * 1999-04-10 2000-10-19 Aventis Res & Tech Gmbh & Co Verfahren zur Herstellung von Biarylen
FR2801584B1 (fr) * 1999-11-26 2003-05-30 Rhodia Chimie Sa Procede de preparation d'un compose polyaromatique
US6984756B2 (en) * 2000-05-19 2006-01-10 Eli Lilly And Company Process for preparing biphenyl compounds
RU2279428C2 (ru) * 2000-09-18 2006-07-10 Эйсай Ко., Лтд. Производные пиридазинона и триазинона и их применение в качестве фармацевтических препаратов
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
AU2003270701B2 (en) * 2002-10-31 2009-11-12 Amgen Inc. Antiinflammation agents
US20040167165A1 (en) * 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associated with an Edg-7 receptor
TW200505902A (en) * 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
US20060264439A1 (en) * 2005-05-17 2006-11-23 Supergen, Inc. Inhibitors of polo-like kinase-1
GB0521563D0 (en) * 2005-10-21 2005-11-30 Glaxo Group Ltd Novel compounds
US7465795B2 (en) * 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
JP5148507B2 (ja) * 2005-12-20 2013-02-20 アストラゼネカ・アクチエボラーグ Ｇａｂａａ受容体調節物質としての置換シンノリン誘導体及びその合成法

Also Published As

Publication number Publication date
UY31161A1 (es) 2009-01-30
US20080318925A1 (en) 2008-12-25
IL202496A0 (en) 2010-06-30
WO2008155573A1 (en) 2008-12-24
TW200911760A (en) 2009-03-16
JP2010530406A (ja) 2010-09-09
AU2008264985A1 (en) 2008-12-24
BRPI0813253A2 (pt) 2014-12-30
US20100184738A1 (en) 2010-07-22
EP2167091A1 (en) 2010-03-31
KR20100039340A (ko) 2010-04-15
CA2691648A1 (en) 2008-12-24
AR067028A1 (es) 2009-09-30
CL2008001837A1 (es) 2009-06-26
PE20090771A1 (es) 2009-07-23

Similar Documents

Publication Publication Date Title
ECSP088450A (es) Derivados de pirimidina 4-(3-aminopirazol) para uso como inhibidores de tirosina quinasa en el tratamiento de cáncer
NI201100137A (es) Derivados de sulfonamida
UY28708A1 (es) Heterociclos sustituídos y usos de los mismos
UY31083A1 (es) Derivados de sulfoximinas para la inhibicion de b-secretasa
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
HN2012001162A (es) Triazolopiridinas
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
CL2008003690A1 (es) Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos.
CL2008000946A1 (es) Compuestos derivados de pirrolopirimidina, inhibidores de cianasa jak3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de rechazo de transplantes, enfermedades autoinmun
ECSP10010693A (es) Compuestos pirazólicos 436
GT200800187A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
UY31906A (es) Derivados de n-cicloalquil-3-fenilnicotinamida que inhiben pgds, sus composiciones, su uso para el tratamiento por ejemplo de afecciones alérgicas y respiratorias.
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
PA8803201A1 (es) Derivados acidos de cicloalquilamino
NO20090313L (no) Derivater og analoger av N-etylkinoloner og N-etylazakinoloner
ECSP099722A (es) Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncer
ECSP088925A (es) Nitrilos espirocíclicos como inhibidores de proteasa
UY30032A1 (es) Compuestos de cinolina, composiciones farmacéuticas que los contienen y procesos para la preparación y uso de los mismos
CR11859A (es) Composición y proceso-356
GT200600117A (es) Nuevos compuestos farmaceuticos
BRPI0914454A2 (pt) "composição para o tratamento do tecido epitelial"
UY31161A1 (es) Usos de derivados de cinolina en el tratamiento de la esquizofrenia
UY30788A1 (es) Compuestos quimicos